Search
Pazopanib
go.drugbank.com/drugs/DB06589ApprovedInvestigationalPazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MGPanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Casopitant
go.drugbank.com/drugs/DB06634InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Neurokinin-1 Receptor AntagonistsArbekacin
go.drugbank.com/drugs/DB06696InvestigationalOften used for treatment of multi-resistant bacterial infection such as methicillin-resistant _Staphylococcus aureus_ (MRSA).
Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic IndexDexmethylphenidate
go.drugbank.com/drugs/DB06701ApprovedInvestigationalDexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002[A177181]. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant[A177193]. … The d-isomer is thought to have greater effect with fewer side effects than the l-isomer or the racemic mixture[A177181].
Categories: Heterocyclic Compounds, 1-RingSynonyms: methyl (R)-phenyl[(R)-piperidin-2-yl]acetate, D-TMPIobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalIodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
Salts: Iobenguane I 123, Iobenguane I 131Categories: Compounds used in a research, industrial, or household settingLodoxamide
go.drugbank.com/drugs/DB06794ApprovedLodoxamide is a mast-cell stabilizer for topical administration into the eye. … Lodoxamide is marketed under the brand name Alomide by Alcon.
Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamateProducts: THILOMIDE GÖZ DAMLASI, 5 ML, ALOMİDE % 0.1 GÖZ DAMLASI, ÇÖZELTİ, 5 MLRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalRaltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. … Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Categories: Heterocyclic Compounds, 1-RingProducts: ISENTRESS® 600MG TABLETAS, ISENTRESS-G TABLET 400MGTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigationalTriethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. … [A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and
Categories: Compounds used in a research, industrial, or household setting